Slide 1: Full Year Results FY26
Full Year Results FY26 Paul Anderson, CEO and Managing Director Andrew Thomson, CFO 19 August 2026
Slide 2: Important Information: Forward-looking statements
Important Information: Forward-looking statements This presentation may contain forward-looking statements regarding Healius Limited’s financial performance, guidance and business prospects. These statements are subject to risks and uncertainties, many beyond the company’s control and are based on m
Slide 3: Group Overview
Group Overview Paul Anderson Chief Executive Officer & Managing Director 3 Healius FY26 Results Presentation
Slide 4: Group Results
Group Results Revenue growth on reduced volumes and higher average fee Underlying Revenue Pathology Revenue Financial Performance Revenue $1,373.2m $1,329.6m • Group revenue growth of $28.7m or 2.1% to $1,373.2m. $1,344.5m in pcp (up 2.1%) $1,306.4m in pcp (up 1.8%) • Pathology revenue growth of $23
Slide 5: Pathology
Pathology Revenue growth on changing revenue mix against flat costs improves margins Strategic Operational • Margin recovery through improving revenue quality and strict cost • Pathology revenue growth attributable to change in revenue mix (growth discipline. in Genomic Diagnostics, B2B including Cl
Slide 6: Agilex Biolabs
Agilex Biolabs Strategic capability enhancement and focus on large molecule development contributes positively Strategic Operational • Healius has engaged UBS Securities Australia Limited to explore a sale • Strategic decision to enhance capability and focus on large molecule of Agilex Biolabs. deve
Slide 7: T27 Scorecard – Performance Update FY26
T27 Scorecard – Performance Update FY26 ✓ Delivery complete ▸ Partially delivered > On track Our aim is to deliver mid-to-high single-digit EBIT margins by December 2028 ✓• Collections: >80% of ACC episodes now processed through Medway Collections ▸• Collections: New HubSpot CRM capability implement
Slide 8: Summary Financials
Summary Financials Andrew Thomson Chief Financial Officer 8 Healius FY26 Results Presentation
Slide 9: Group Results
Group Results Focused on cost reduction strategy FY26 FY25 Top line revenue growth / cost reductions $m $m Chg % • Group underlying revenue growth of $28.7m (2.1%) to $1,373.2m driven by Underlying Revenue 1,373.2 1,344.5 2.1% improved mix in Pathology and strong revenue growth in Agilex. • Group EB
Slide 10: Pathology
Pathology Improved revenue source mix contributing to average fee growth FY26 FY25 Revenue growth 1.8% - benefiting from mix UNDERLYING $m $m Chg % • Revenue growth underpinned by improved mix of Specialists, Hospital Revenue 1,329.6 1,306.4 1.8% and B2B revenues leading to higher average fees. EBIT
Slide 11: Agilex Biolabs
Agilex Biolabs Strategic pivot to large molecule work contributes to margin expansion, well positioned to capitalise on market growth FY26 FY25 Revenue growth contributing to margin UNDERLYING $m $m Chg % improvement and expansion Revenue 43.6 38.2 14.1% • EBIT margin of 14.7% reflects the change in
Slide 12: Capital Management
Capital Management Conservative capital management until earnings consistency is achieved Net cash bridge ($m) Capex • Maintenance capex of $16.5m (FY25: $31.3m), primarily (19.6) for replacement of aged laboratory equipment and IT (22.4) hardware. • Growth capex of $26.8m (FY25: $34.6m) mainly cons
Slide 13: FY27 Outlook
FY27 Outlook Healius expects FY27 EBIT to be in line with consensus1 EBIT of $39.7m. Pathology • Healius anticipates volumes to grow in line with MBS on a like-for-like collection centre basis, in addition to a modest increase in profitable sites. Non-MBS volumes are expected to see the benefit of a
Slide 14: Q&A
Q&A 14 Healius FY26 Results Presentation
Slide 15: Appendix
Appendix 15 Healius FY26 Results Presentation
Slide 16: Pathology Strategy
Pathology Strategy Execution of strategy well underway with a defined plan and progress Focused on providing better services for our patients and referrers to improve the volume and quality of the revenue we generate and to become more efficient in our processes Customer Laboratory Emerging Enabled
Slide 17: Underlying to Reported Reconciliation
Underlying to Reported Reconciliation FY26 FY25 FY26 FY25 $m $m $m $m Underlying EBIT 30.2 17.1 Underlying EBIT 30.2 17.1 Termination and other costs (16.6) (10.8) Interest (49.1) (65.1) Digital transformation costs (9.2) (19.6) Notional interest recharged to Lumus Imaging, net of tax - 12.6 Transac
Slide 18: Thank you
Thank you The Healius Pathology Network incorporating Abbott Pathology | Dorevitch Pathology | Laverty Pathology | QML Pathology TML Pathology | Western Diagnostic Pathology | Gastrolab | Genomic Diagnostics IQ Pathology | Kossard Dermatopathologists | Vetnostics Pathology